22
Last reporting period 31 Dec, 2023
Updated 19 Sep, 2024
Last price
—
Market cap $B
6.523
Exchange
XHKG - Hong Kong Exchange
1.9 B
Last period CFO ,CNY
200%
CFO has increased in 5 years
What is CFO ?
Operating cash flow is the difference between the income and expenses of cash that is generated as a result of the main activities of the company.
See also WuXi Biologics
Company Analysis
2269.HK valuation, rating, competitors, insights and company profile
Eyestock Rating
2269.HK financial analysis by Eyestock methodology
Valuation
2269.HK valuation using historical relative method
Statements
2269.HK Income Statements, Balance Sheet and Cash Flow Statements
Dividends
2269.HK dividend yield and annual dividend
Operating cash flow is the difference between the income and expenses of cash that is generated as a result of the main activities of the company.
WuXi Biologics`s CFO for the period ended 2023-12-31 is 1.9 B CNY
